Copyright
©The Author(s) 2016.
World J Gastroenterol. Oct 28, 2016; 22(40): 8967-8977
Published online Oct 28, 2016. doi: 10.3748/wjg.v22.i40.8967
Published online Oct 28, 2016. doi: 10.3748/wjg.v22.i40.8967
Figure 6 Changes in serum creatinine levels and eGFR of patients administered with deferasirox.
A: All patients showed gradual increase in creatinine levels after initiation of DFX treatment, until reduction in DFX dose or discontinuation of treatment. Creatinine levels in all patients were improved by dose reduction. B: All patients showed gradual decrease in eGFR after initiation of DFX treatment, until reduction in DFX dose or discontinuation of treatment.
- Citation: Saeki I, Yamamoto N, Yamasaki T, Takami T, Maeda M, Fujisawa K, Iwamoto T, Matsumoto T, Hidaka I, Ishikawa T, Uchida K, Tani K, Sakaida I. Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma. World J Gastroenterol 2016; 22(40): 8967-8977
- URL: https://www.wjgnet.com/1007-9327/full/v22/i40/8967.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i40.8967